Kornimate/medical-research-clean huggingface dataset:
first-degree ankle sprains

Conditions: Ankle Sprain 1St Degree

Summary: grade i ankle sprains are common, especially among athletes, women, teenagers, and physically active individuals. while over a million cases are reported annually, this represents only half of the total occurrences. these injuries can lead to complications like chronic ankle instability or osteoarthritis. treatment often involves conservative methods, including the pricemms protocol (protection, rest, ice, compression, elevation, modalities, medication, and support), while surgery is reserved for severe cases. therapeutic exercises and rehabilitation play a key role in recovery. the bowen technique, effective for other musculoskeletal issues, has not yet been extensively studied for grade i ankle sprains.


Eligibility criteria:
inclusion criteria: * individuals diagnosed with grade i acute ankle sprain confirmed by a specialist physician in radiology, * age of participants ≥ 18 years, * individuals of both sexes exclusion criteria: * recurrent ankle injury, * acute ankle sprains of grade ii and iii, * presence of other physical and/or mental health issues.

Keywords: ankle sprain bowen technique
safety and efficacy study of umbilical cord/placenta-derived mesenchymal stem cells to treat severe aplastic anemia

Conditions: Aplastic Anemia

Summary: the purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (mscs) derived from human umbilical cord/placenta at a dose of 1.0e+6 msc/kg in subject for the therapy of severe aplastic anemia (saa).

severe aplastic anemia (saa) is a condition that involves a low level of red blood cells, white blood cells, and platelets without evidence of another bone marrow disease. patients with severe aplastic anemia produce too few blood cells, causing fatigue, easy bruising and bleeding, and susceptibility to infections. in many cases, the very low blood counts result from an autoimmune process. the patient's own immune system damages their stem cells in bone marrow. although immune-suppressing drugs, such as corticosteroids, csa and atg, have been used in the treatment of saa, however, many studies have indicated that the overall response rate to these drugs is less than 60%. addition, the severe side effects of these immune-suppressing drugs have also been observed. the management of saa patients therefore remains unsatisfactory and targeted therapies are needed. human mscs isolated from human umbilical cord/placenta have been shown to have immunosuppressive, stimulating hematopoiesis and tissue repairing properties. this study will evaluate the safety and effectiveness of msc transplantation in the saa patients. this study will last 2 to 3 years. participants will be randomly assigned to receive either msc transplant and csa therapy (experimental group) or csa therapy alone (control group). patients will undergo msc transplant at the start of the study on day 0. after 3 months, patients will receive the second msc transplantation. after six and twelve months from the first transplantation, patients will be evaluated.

Eligibility criteria:
inclusion criteria: 1. patient age 18\~80 years old with plan to infuse mscs. 2. standard of diagnosis of aplastic anemia is according to chinese domestic classification of aa for 1987. 3. patients must have an ecog 0\~2. 4. no moderate or sever organ dysfunction: ejection fraction\>45%; creatinine \<176 umol/l. 5. no active severe viral or fungus infection. 6. each patient must sign written informed consent. exclusion criteria: 1. psychiatric condition that would limit informed consent. 2. hiv positive 3. positive pregnancy test 4. patient has enrolled another clinical trial study within last 4 weeks.

Keywords: bone marrow disease aplastic anemia umbilical cord/placenta-derived msc transplantation
safety, tolerability, pharmacokinetics and pharmacodynamics study of amg 890 in subjects with elevated plasma lipoprotein(a)

Conditions: Cardiovascular Disease

Summary: this is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma lipoprotein(a) \[lp(a)\]. amg 890 will be evaluated in approximately 80 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.


Eligibility criteria:
inclusion criteria: * men and women with ages between 18 and 70 years old, inclusive. * protocol-defined elevated plasma lp(a) level. * body mass index (bmi) greater than or equal to 18 and less than or equal to 40 kg/m2, at screening. * women must be of non-reproductive potential. * other inclusion criteria may apply exclusion criteria: * currently receiving treatment in another investigational device or drug study. * women who are lactating/breastfeeding or who plan to breastfeed while on study or through 90 days after receiving the last dose of investigational product (for subjects who withdraw prior to end of study). * history or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. * history or clinical evidence of bleeding diathesis or any coagulation disorder. * history or clinical evidence of peripheral neuropathy. * other exclusion criteria may apply
human epidermal growth factor receptor 2 (her2) advanced gastric epidemiology study in korea

Conditions: Gastric Cancer; Gastroesophageal Junction Cancer

Summary: this study is designed to gather epidemiological data in korea on her2 incidence in gastric and gastroesophageal junction cancer as assessed by local laboratories in a real-life setting. no investigational products will be provided or evaluated.


Eligibility criteria:
inclusion criteria: * formalin-fixed, paraffin-embedded tumor tissue samples with histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction with locally advanced, recurrent, and/or metastatic disease * sufficient invasive tumor tissue for her2 evaluation, including surgical excision specimens or at least 6 to 8 available biopsies exclusion criteria: * none specified
use of intraoral suction and its effects on obstructive sleep apnea

Conditions: Obstructive Sleep Apnea of Adult

Summary: to learn whether stabilization of the tongue using intraoral suction is tolerable and what effects this approach has on sleep parameters in obstructive sleep apnea.

patients who are newly diagnosed with moderate osa or diagnosed with osa in the past 5 years and who are not compliant with continuous positive airway pressure treatment will be identified from the boston va healthcare sleep laboratory database and invited to participate in the study. those patients interested in participating will be consented and then evaluated for adequate nasal patency and oral dentition to assess their eligibility for the study. this is a pilot study primarily assessing tolerability of using intraoral suction to stabilise the tongue at night as well as its effects on sleep parameters. target enrollment is 40 patients. those enrolled will have a digital intra-oral scan performed and a custom-fit mouthguard that can transmit low level intermittent suction fabricated. the participant will wear this mouthguard for up to five consecutive nights. they will complete a survey designed to assess tolerability following five nights of wearing the mouthguard. the participant will then have a two night in-hospital polysomnography performed one night with the mouthguard transmitting suction and a second night with no suction. the outcomes will be measured using the tolerability survey scores and the duration and quality of sleep as measured by polysomnography.

Eligibility criteria:
inclusion criteria: age 18-80 patients newly diagnosed with osa (a diagnosis of osa ≤6 months) who may or may not have started using their pap yet patients diagnosed \> 6 months but within the past 5 years who are not compliant with positive airway pressure treatment. non compliance is defined as use of device for an average of \<4 hours/night or \< 5 nights/week an ahi, rei or rdi or any synonymous term for ahi in the moderate to severe range (15-60) a body mass index (bmi) less than \<=40 (bmi within 1 year of enrollment date) adequate dentition to support a dental retainer exclusion criteria: evidence of central sleep apnea or concomitant sleep disorder other than osa currently using mad or other form of mouth prosthesis to treat osa prior surgical treatment for osa history of anatomic nasal obstruction use of medications that may affect sleep (hypnotic medications for the treatment of insomnia) use of pacemaker or implantable cardioverter-defibrillator (icd) immunocompromised (i.e., susceptible to infection) open soars/wounds in patient's mouth active alcohol abuse or iv drug use
efficacy of ciclesonide inhaled once daily versus fluticasone propionate inhaled twice daily in children with asthma (6 to 11 y) (by9010/m1-206)

Conditions: Asthma

Summary: the aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function, symptoms, and use of rescue medication in children with persistent asthma. ciclesonide will be inhaled once daily, using one of the two dose levels; fluticasone propionate will be inhaled at one dose level twice daily. the study duration consists of a baseline period (2 to 4 weeks) and a treatment period (12 weeks). the study will provide further data on safety and tolerability of ciclesonide.


Eligibility criteria:
main inclusion criteria: * history of persistent bronchial asthma for at least 6 months * fev1 50-90% of predicted main exclusion criteria: * concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids * copd (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function * respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study * history of life-threatening asthma * premature birth * current smoking * smoking history with either equal or more than 10 pack-years * pregnancy * intention to become pregnant during the course of the study * breast feeding * lack of safe contraception

Keywords: asthma ciclesonide child fluticasone propionate pediatric
zinc-containing vaginal gel and oral fluconazole for vulvovaginal candidiasis.

Conditions: Vulvovaginal Candidiasis; Vaginal Yeast Infections

Summary: vaginitis is one of the most common gynecological problems in women. candida albicans is responsible for more than 85% of vaginal fungal infections and reinfection after standard treatment is quite common. the aim of this study is to compare the effects of a zinc-containing vaginal gel and oral fluconazole on the treatment and recurrence of vulvovaginal candidiasis (vvc). the investigator's hypothesis is that zinc-containing vaginal gel may decrease the rate of reinfection after standard treatment with oral 150 mg fluconazole.

randomized controlled trial will be conducted on 76 women with vvc, as confirmed by clinical and laboratory diagnosis. the participants will be allocated into two groups using blocked randomization method. in the control group participants will receive oral fluconazole treatment with a single dose of oral fluconazole (150 mg) while in the treatment group women will receive a single oral dose of fluconazole (150mg) followed by treatment with a zinc-containing vaginal gel (daily for 2 weeks and twice per week thereafter). vaginal samples will be collected (vaginal swab and cervicovaginal lavage) at baseline and 4-8-12 weeks after starting treatment. in addition, the clinical signs and symptoms will be assessed before the intervention and follow-ups. women will be asked to report any new symptoms of vaginal infections and will be asked to return for in-office evaluation.

Eligibility criteria:
inclusion criteria: * healthy, nonpregnant female participants aged ≥18 years with a clinical diagnosis of symptomatic acute vvc. * positive baseline potassium hydroxide (koh) wet mount from a vaginal smear revealing filamentous hyphae/pseudohyphae or budding yeast cells. * presence of ≥1 vulvovaginal sign. * presence of ≥1 vulvovaginal symptom. * composite candida severity score of ≥4. exclusion criteria: * abnormal papanicolaou smear in the preceding 12 months. * patients who had oral or intravenous antifungal agents within 4 weeks, or used topical vaginal antifungal drugs within 1 week before the study. * known human immunodeficiency virus infection, * liver disease or abnormal liver function tests, lactation, pregnancy, and allergy to azole agents or zinc. * women with non-albicans candida species will be excluded from the final data analysis.
pilot study investigating intensity and quality of movement performed during a parkiboks session

Conditions: Parkinson Disease

Summary: studies have shown that non-contact boxing benefits individuals with parkinson disease. yet, the content of such sessions, has not yet been investigated. the following research question has therefore been asked: what is the physical intensity, in terms of both movement quality and quantity, as well as cardiovascular demand, in a group of individuals with parkinson's disease during a one-hour session of parkiboks? though the study is exploratory, the investigators hypothesize to observe increases in cardiovascular activity during the session, as well as a high number of upper-limb repetitions of near maximal range of motion.


Eligibility criteria:
inclusion criteria: * official diagnosis of parkinson disease active participants of a non-contact boxing group for people with parkinson disease located in turnhout, belgium participating in non-contact boxing sessions for at least one month prior to the study exclusion criteria: * unable to read and understand the informed consent document individuals who are wheelchair-bound
investigation of the effects of balance training on balance and functional status patients with total hip arthroplasty

Conditions: Arthroplasty Complications; Physical Disability; Osteoarthritis, Hip

Summary: the purpose of this study is to investigate the effects of balance training in patients with tha until 26 weeks postoperatively. thirty-two patients with hip osteoarthritis who were candidates for tha were recruited to the study. sixteen patients with tha completed the study protocol and the patients were randomized into 2 groups: conventional rehabilitation (cr, n=8) or conventional rehabilitation plus balance training (cr + bt, n=8) groups. the patients were evaluated by hand-held dynamometer, single leg stance test (slst), tetrax balance system, harris hip score, lower extremity function scale, 5 times sit-to-stand test and 50 foot timed walk test preoperatively and in the 8th, 14th and 26th weeks postoperatively.


Eligibility criteria:
inclusion criteria: * total hip arthroplasty due to osteoarthritis * first time hip surgery/prothesis * no involvement in any exercise program in the past 12 months exclusion criteria: * tha due to hip fracture, * revision hip prothesis, * arthritis in other joints limited function * neurologic problems that limited function and balance, * body mass index greater than 40 kg/m2.

Keywords: osteoarthritis hip total hip arthroplasty balance training function assessment
effects of surgical correction of nasal obstruction on oxygen uptake and ventilation volume

Conditions: Nasal Obstruction; Septoplasty Surgeries; Athletic Performance

Summary: this retrospective study aims to evaluate the effect of surgical correction of nasal obstruction on aerobic performance parameters in male athletes aged 20-32 years. the main questions it aims to answer are: * does nasal obstruction surgery impact running economy and ventilation during exercise? * does it affect oxygen consumption during submaximal running efforts? researchers will retrospectively compare male athletes who underwent nasal obstruction surgery (experimental group) to matched athletes without nasal obstruction (control group) to assess changes in respiratory function and exercise performance. participants were assessed by: * acoustic rhinometry to measure nasal cavity dimensions. * the nasal obstruction symptom evaluation (nose) scale and epworth sleepiness scale (ess) to evaluate nasal obstruction symptoms and daytime sleepiness. * incremental treadmill exercise tests to collect data on gas exchange, oxygen consumption, ventilation, and running economy before and after the surgical intervention (or across a similar time period for the control group).


Eligibility criteria:
inclusion criteria: for experimental group (eg): * diagnosed with nasal obstruction due to septal deviation and/or inferior turbinate hypertrophy * experiencing nasal breathing difficulties and sleep disturbance * deemed eligible for septoplasty and/or inferior turbinoplasty following physical and endoscopic examination * voluntarily agreed to participate in the study * for control group (cg): * no reported nasal obstruction or breathing complications * matched with eg participants by age, sport discipline, training level, and vo₂max (with a maximum variation of ±5%) * willing to follow a similar training program to their matched eg counterparts between pre- and post-testing periods exclusion criteria: * history of nasal surgery * presence of cardiopulmonary diseases * musculoskeletal disorders affecting physical performance or exercise testing * inability or unwillingness to follow the pre- and post-test training schedule * any surgical complication that would interfere with post-operative participation in physical testing (note: none occurred in this study)

Keywords: nasal surgery aerobic performance exercise economy respiratory work
human fibrinogen - pharmacokinetics

Conditions: Fibrinogen Deficiency

Summary: this study evaluated the single-dose pharmacokinetics of human fibrinogen concentrate and clot strength (maximum clot firmness \[mcf\]) in subjects with congenital fibrinogen deficiency. mcf was measured to demonstrate the functional activity of replacement fibrinogen when a fixed dose of human fibrinogen concentrate was administered.


Eligibility criteria:
inclusion criteria: * aged ≥ 6 years * documented congenital fibrinogen deficiency: fibrinogen deficiency manifested as afibrinogenemia with plasma fibrinogen activity and antigen at screening undetectable (i.e. \< 20 mg/dl) * informed consent signed by subject or legal guardian exclusion criteria: * presence or history of hypersensitivity to human fibrinogen concentrate or human plasma proteins, * presence or history of deep vein thrombosis, pulmonary embolism, or arterial thrombosis * acute bleeding * history of esophageal varicose bleeding * end stage liver disease (i.e. child-pugh score b or c) * planned major surgery with a need for blood transfusion during the pk blood sampling period * polytrauma within 1 year prior to enrollment

Keywords: congenital fibrinogen deficiency fibrinogen concentrate pharmacokinetics thrombelastography
a study of ly3556050 in adult participants with diabetic peripheral neuropathic pain

Conditions: Diabetic Peripheral Neuropathy

Summary: the main purpose of this study is to determine the safety and efficacy of ly3556050 versus placebo in participants with diabetic peripheral neuropathic pain (dpnp). the study will lasts approximately 24 weeks, across 3 study periods.


Eligibility criteria:
inclusion criteria: * have a history and current diagnosis of type 1 diabetes (t1d) or type 2 diabetes (t2d) diagnosed for at least 6 months prior to screening. * have a stable glycemic control on stable diabetes treatment regimen for at least 90 days prior to day 1 with a hemoglobin a1c (hba1c) ≤10 for t1d and hba1c ≤11 for participants with t2d at time of screening. * have a history of daily peripheral neuropathic pain for at least 12 weeks based on participant report or medical history. * have a visual analog scale (vas) pain value ≥40 and \<95 during screening. * have presence of diabetic peripheral neuropathy of symmetrical nature and in lower extremities for ≥6 months and diagnosed by a score of part b ≥3 on michigan neuropathy screening instrument * are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation. * are willing to discontinue all medications taken for chronic pain conditions, except allowed concomitant pain medication permitted per protocol, for the duration of the study * have a body mass index ≤45 kilogram/square meter (kg/m²) (inclusive). * are men, or women able to abide by reproductive and contraceptive requirements. exclusion criteria: * history of other potentially causative and/or confounding sources of pain that may impair self-assessment of pain due to dpnp. * have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques. * have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision. * are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide. * have in the judgement of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation. * have a positive hiv test result at screening. * have a surgery planned during the study for any reason. * have a substance use disorder as defined by the diagnostic and statistical manual of mental disorders (5th edition; dsm-5; american psychiatric association)
impact of exclusive enteral nutrition therapy on sperm quality of patients with crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to investigate the impact of enteral nutrition therapy on sperm quality of patients with crohn's disease.

the highest age- and sex-adjusted incidence rates for crohn's disease (cd) occur during the peak reproductive years. in addition, gastroenterologists frequently advise and manage patients with cd who desire to conceive. enteral nutrition therapy is effective for induction and maintenance of remission in reproductive age men with cd. however, there is no available data on the effects of enteral nutrition therapy on semen quality. the purpose of this study is to investigate the impact of enteral nutrition therapy on sperm quality of patients with cd.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of crohn' disease * male patients * age: 18-40 years old * receive 3-months exclusive enteral nutrition therapy exclusion criteria: * used any experimental therapy in the 8 weeks before study entry date * had previously documented problems with male reproductive health, such as low sperm count, impotence, or malignancy * the use of concomitant medication including sulphasalazine, 5-aminosalicylic acid or other immune-suppressives. * unable to complete the 3-months exclusive enteral nutrition therapy.

Keywords: crohn's disease semen quality enteral nutrition cdai score higher than 150